Skip to main content
NCBI home page
Infection and Immunity logoLink to Infection and Immunity
. 1993 May;61(5):2122–2130. doi: 10.1128/iai.61.5.2122-2130.1993

Abrogation of suppression of delayed hypersensitivity induced by Candida albicans-derived mannan by treatment with monophosphoryl lipid A.

J E Domer 1, L G Human 1, G B Andersen 1, J A Rudbach 1, G L Asherson 1
PMCID: PMC280812  PMID: 8478102

Abstract

Monophosphoryl lipid A (MLA), derived either from Salmonella minnesota or Salmonella typhimurium, was tested for its ability to alter Candida albicans mannan (MAN)-specific suppression. Since we showed previously that naive mice injected intravenously (i.v.) with MAN developed suppressor T cells capable of down-regulating delayed-type hypersensitivity when transferred to immunized recipients, MLA was tested for its ability to influence suppressor activity in the donors of suppressor cells. T-lymphocyte-enriched suspensions from donor mice treated with MLA, especially that derived from S. typhimurium, 2 or 3 days after the injection of MAN lost the ability to suppress delayed-type hypersensitivity when transferred to immunized mice. Transferable suppressor activity was reduced but not always completely abrogated when donor animals were treated with MLA 1 day following the administration of MAN. In several experiments, S. minnesota MLA also abrogated activity, but it was not effective in other transfer experiments. In a different type of experiment, MLA was given to immunized mice which had been suppressed directly with MAN. Mice were immunized, either by the introduction of C. albicans intragastrically followed by inoculation intradermally (i.d.) or by two i.d. inoculations, and MAN-specific suppressor cells were induced in such animals by the i.v. injection of MAN 1 day before the first or second i.d. inoculation in animals given intragastric plus i.d. inoculations and those given two i.d. inoculations, respectively. MLA was administered to such mice prior to the i.v. injection of MAN, on the same day, or 1 to 4 days thereafter. S. typhimurium MLA, especially when given to mice 2 days following the administration of MAN, caused a partial abrogation of suppressor activity. Overall, however, MLA, at 5 to 100 micrograms, had variable and minimal effects on suppressor activity in immunized mice suppressed by the i.v. administration of MAN. In summary, MLA is clearly capable of abrogating MAN-induced suppression when given to nonimmunized animals in which MAN-specific suppressor cells had been induced, but its efficacy in immunized animals suppressed by the i.v. administration of MAN was marginal.

Full text

PDF
2122

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alving C. R., Richards R. L. Liposomes containing lipid A: a potent nontoxic adjuvant for a human malaria sporozoite vaccine. Immunol Lett. 1990 Aug;25(1-3):275–279. doi: 10.1016/0165-2478(90)90127-c. [DOI] [PubMed] [Google Scholar]
  2. Baker P. J., Haslov K. R., Fauntleroy M. B., Stashak P. W., Myers K., Ulrich J. T. Enrichment of suppressor T cells by means of binding to monophosphoryl lipid A. Infect Immun. 1990 Mar;58(3):726–731. doi: 10.1128/iai.58.3.726-731.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Baker P. J., Hiernaux J. R., Fauntleroy M. B., Prescott B., Cantrell J. L., Rudbach J. A. Inactivation of suppressor T-cell activity by nontoxic monophosphoryl lipid A. Infect Immun. 1988 May;56(5):1076–1083. doi: 10.1128/iai.56.5.1076-1083.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Baker P. J., Hiernaux J. R., Fauntleroy M. B., Stashak P. W., Prescott B., Cantrell J. L., Rudbach J. A. Ability of monophosphoryl lipid A to augment the antibody response of young mice. Infect Immun. 1988 Dec;56(12):3064–3066. doi: 10.1128/iai.56.12.3064-3066.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Carswell E. A., Old L. J., Kassel R. L., Green S., Fiore N., Williamson B. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci U S A. 1975 Sep;72(9):3666–3670. doi: 10.1073/pnas.72.9.3666. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Chen Y. F., Solem L., Johnson A. G. Activation of macrophages from aging mice by detoxified lipid A. J Leukoc Biol. 1991 Apr;49(4):416–422. doi: 10.1002/jlb.49.4.416. [DOI] [PubMed] [Google Scholar]
  7. Domer J. E., Garner R. E., Befidi-Mengue R. N. Mannan as an antigen in cell-mediated immunity (CMI) assays and as a modulator of mannan-specific CMI. Infect Immun. 1989 Mar;57(3):693–700. doi: 10.1128/iai.57.3.693-700.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Domer J. E., Hector R. F. Enhanced immune responses in mice treated with penicillin-tetracycline or trimethoprim-sulfamethoxazole when colonized intragastrically with Candida albicans. Antimicrob Agents Chemother. 1987 May;31(5):691–697. doi: 10.1128/aac.31.5.691. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Ekwunife F. S., Taylor C. E., Fauntleroy M. B., Stashak P. W., Baker P. J. Differential effects of monophosphoryl lipid A on expression of suppressor T cell activity in lipopolysaccharide-responsive and lipopolysaccharide-defective strains of C3H mice. Infect Immun. 1991 Jun;59(6):2192–2194. doi: 10.1128/iai.59.6.2192-2194.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Espevik T., Figari I. S., Shalaby M. R., Lackides G. A., Lewis G. D., Shepard H. M., Palladino M. A., Jr Inhibition of cytokine production by cyclosporin A and transforming growth factor beta. J Exp Med. 1987 Aug 1;166(2):571–576. doi: 10.1084/jem.166.2.571. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Esquivel F., Taylor C. E., Baker P. J. Differential sensitivity of CD8+ suppressor and cytotoxic T lymphocyte activity to bacterial monophosphoryl lipid A. Infect Immun. 1991 Sep;59(9):2994–2998. doi: 10.1128/iai.59.9.2994-2998.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Fischer A., Ballet J. J., Griscelli C. Specific inhibition of in vitro Candida-induced lymphocyte proliferation by polysaccharidic antigens present in the serum of patients with chronic mucocutaneous candidiasis. J Clin Invest. 1978 Nov;62(5):1005–1013. doi: 10.1172/JCI109204. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Fischer A., Pichat L., Audinot M., Griscelli C. Defective handling of mannan by monocytes in patients with chronic mucocutaneous candidiasis resulting in a specific cellular unresponsiveness. Clin Exp Immunol. 1982 Mar;47(3):653–660. [PMC free article] [PubMed] [Google Scholar]
  14. Fitzgerald T. J. Syphilis vaccine: up-regulation of immunogenicity by cyclophosphamide, Ribi adjuvant, and indomethacin confers significant protection against challenge infection in rabbits. Vaccine. 1991 Apr;9(4):266–272. doi: 10.1016/0264-410x(91)90110-r. [DOI] [PubMed] [Google Scholar]
  15. Fitzgerald T. J., Tomai M. A. Splenic T-lymphocyte functions during early syphilitic infection are complex. Infect Immun. 1991 Nov;59(11):4180–4186. doi: 10.1128/iai.59.11.4180-4186.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Fung P. Y., Madej M., Koganty R. R., Longenecker B. M. Active specific immunotherapy of a murine mammary adenocarcinoma using a synthetic tumor-associated glycoconjugate. Cancer Res. 1990 Jul 15;50(14):4308–4314. [PubMed] [Google Scholar]
  17. Garg M., Subbarao B. Immune responses of systemic and mucosal lymphoid organs to Pnu-Imune vaccine as a function of age and the efficacy of monophosphoryl lipid A as an adjuvant. Infect Immun. 1992 Jun;60(6):2329–2336. doi: 10.1128/iai.60.6.2329-2336.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Garner R. E., Childress A. M., Human L. G., Domer J. E. Characterization of Candida albicans mannan-induced, mannan-specific delayed hypersensitivity suppressor cells. Infect Immun. 1990 Aug;58(8):2613–2620. doi: 10.1128/iai.58.8.2613-2620.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Gautam S. C., Chikkala N. F., Hamilton T. A. Anti-inflammatory action of IL-4. Negative regulation of contact sensitivity to trinitrochlorobenzene. J Immunol. 1992 Mar 1;148(5):1411–1415. [PubMed] [Google Scholar]
  20. Gery I., Krüger J., Spiesel S. Z. Stimulation of B-lymphocytes by endotoxin. Reactions of thymus-deprived mice and karyotypic analysis of dividing cells in mice bearing T 6 T 6 thymus grafts. J Immunol. 1972 Apr;108(4):1088–1091. [PubMed] [Google Scholar]
  21. Gustafson G. L., Rhodes M. J. A rationale for the prophylactic use of monophosphoryl lipid A in sepsis and septic shock. Biochem Biophys Res Commun. 1992 Jan 15;182(1):269–275. doi: 10.1016/s0006-291x(05)80140-8. [DOI] [PubMed] [Google Scholar]
  22. Gustafson G. L., Rhodes M. J. Bacterial cell wall products as adjuvants: early interferon gamma as a marker for adjuvants that enhance protective immunity. Res Immunol. 1992 Jun;143(5):483–574. doi: 10.1016/0923-2494(92)80058-s. [DOI] [PubMed] [Google Scholar]
  23. Henricson B. E., Benjamin W. R., Vogel S. N. Differential cytokine induction by doses of lipopolysaccharide and monophosphoryl lipid A that result in equivalent early endotoxin tolerance. Infect Immun. 1990 Aug;58(8):2429–2437. doi: 10.1128/iai.58.8.2429-2437.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Hiernaux J. R., Stashak P. W., Cantrell J. L., Rudbach J. A., Baker P. J. Immunomodulatory activity of monophosphoryl lipid A in C3H/HeJ and C3H/HeSnJ mice. Infect Immun. 1989 May;57(5):1483–1490. doi: 10.1128/iai.57.5.1483-1490.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Hui G. S., Tam L. Q., Chang S. P., Case S. E., Hashiro C., Siddiqui W. A., Shiba T., Kusumoto S., Kotani S. Synthetic low-toxicity muramyl dipeptide and monophosphoryl lipid A replace Freund complete adjuvant in inducing growth-inhibitory antibodies to the Plasmodium falciparum major merozoite surface protein, gp195. Infect Immun. 1991 May;59(5):1585–1591. doi: 10.1128/iai.59.5.1585-1591.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Ishihara C., Miyazawa M., Nishio J., Azuma I., Chesebro B. Use of low toxicity adjuvants and killed virus to induce protective immunity against the Friend murine leukaemia retrovirus-induced disease. Vaccine. 1992;10(5):353–356. doi: 10.1016/0264-410x(92)90378-w. [DOI] [PubMed] [Google Scholar]
  27. Issekutz T. B., Stoltz J. M., vd Meide P. Lymphocyte recruitment in delayed-type hypersensitivity. The role of IFN-gamma. J Immunol. 1988 May 1;140(9):2989–2993. [PubMed] [Google Scholar]
  28. JOHNSON A. G., GAINES S., LANDY M. Studies on the O antigen of Salmonella typhosa. V. Enhancement of antibody response to protein antigens by the purified lipopolysaccharide. J Exp Med. 1956 Feb 1;103(2):225–246. doi: 10.1084/jem.103.2.225. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Johnson A. G., Tomai M. A. A study of the cellular and molecular mediators of the adjuvant action of a nontoxic monophosphoryl lipid A. Adv Exp Med Biol. 1990;256:567–579. doi: 10.1007/978-1-4757-5140-6_51. [DOI] [PubMed] [Google Scholar]
  30. Johnston D., Bystryn J. C. Effect of cell wall skeleton and monophosphoryl lipid A adjuvant on the immunogenicity of a murine B16 melanoma vaccine. J Natl Cancer Inst. 1991 Sep 4;83(17):1240–1245. doi: 10.1093/jnci/83.17.1240. [DOI] [PubMed] [Google Scholar]
  31. Julius M. H., Simpson E., Herzenberg L. A. A rapid method for the isolation of functional thymus-derived murine lymphocytes. Eur J Immunol. 1973 Oct;3(10):645–649. doi: 10.1002/eji.1830031011. [DOI] [PubMed] [Google Scholar]
  32. Kiener P. A., Marek F., Rodgers G., Lin P. F., Warr G., Desiderio J. Induction of tumor necrosis factor, IFN-gamma, and acute lethality in mice by toxic and non-toxic forms of lipid A. J Immunol. 1988 Aug 1;141(3):870–874. [PubMed] [Google Scholar]
  33. Kocourek J., Ballou C. E. Method for fingerprinting yeast cell wall mannans. J Bacteriol. 1969 Dec;100(3):1175–1181. doi: 10.1128/jb.100.3.1175-1181.1969. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Lei M. G., Morrison D. C. Specific endotoxic lipopolysaccharide-binding proteins on murine splenocytes. I. Detection of lipopolysaccharide-binding sites on splenocytes and splenocyte subpopulations. J Immunol. 1988 Aug 1;141(3):996–1005. [PubMed] [Google Scholar]
  35. Lei M. G., Morrison D. C. Specific endotoxic lipopolysaccharide-binding proteins on murine splenocytes. II. Membrane localization and binding characteristics. J Immunol. 1988 Aug 1;141(3):1006–1011. [PubMed] [Google Scholar]
  36. Lei M. G., Stimpson S. A., Morrison D. C. Specific endotoxic lipopolysaccharide-binding receptors on murine splenocytes. III. Binding specificity and characterization. J Immunol. 1991 Sep 15;147(6):1925–1932. [PubMed] [Google Scholar]
  37. Madonna G. S., Peterson J. E., Ribi E. E., Vogel S. N. Early-phase endotoxin tolerance: induction by a detoxified lipid A derivative, monophosphoryl lipid A. Infect Immun. 1986 Apr;52(1):6–11. doi: 10.1128/iai.52.1.6-11.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Mihara M., Ikuta M., Koishihara Y., Ohsugi Y. Interleukin 6 inhibits delayed-type hypersensitivity and the development of adjuvant arthritis. Eur J Immunol. 1991 Oct;21(10):2327–2331. doi: 10.1002/eji.1830211006. [DOI] [PubMed] [Google Scholar]
  39. Miller A., Lider O., Roberts A. B., Sporn M. B., Weiner H. L. Suppressor T cells generated by oral tolerization to myelin basic protein suppress both in vitro and in vivo immune responses by the release of transforming growth factor beta after antigen-specific triggering. Proc Natl Acad Sci U S A. 1992 Jan 1;89(1):421–425. doi: 10.1073/pnas.89.1.421. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Mitchell M. S., Kan-Mitchell J., Kempf R. A., Harel W., Shau H. Y., Lind S. Active specific immunotherapy for melanoma: phase I trial of allogeneic lysates and a novel adjuvant. Cancer Res. 1988 Oct 15;48(20):5883–5893. [PubMed] [Google Scholar]
  41. Odean M. J., Frane C. M., Van derVieren M., Tomai M. A., Johnson A. G. Involvement of gamma interferon in antibody enhancement by adjuvants. Infect Immun. 1990 Feb;58(2):427–432. doi: 10.1128/iai.58.2.427-432.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Qureshi N., Mascagni P., Ribi E., Takayama K. Monophosphoryl lipid A obtained from lipopolysaccharides of Salmonella minnesota R595. Purification of the dimethyl derivative by high performance liquid chromatography and complete structural determination. J Biol Chem. 1985 May 10;260(9):5271–5278. [PubMed] [Google Scholar]
  43. Qureshi N., Takayama K., Ribi E. Purification and structural determination of nontoxic lipid A obtained from the lipopolysaccharide of Salmonella typhimurium. J Biol Chem. 1982 Oct 10;257(19):11808–11815. [PubMed] [Google Scholar]
  44. Ribi E. E., Granger D. L., Milner K. C., Strain S. M. Tumor regression caused by endotoxins and mycobacterial fractions. J Natl Cancer Inst. 1975 Nov;55(5):1253–1257. doi: 10.1093/jnci/55.5.1253. [DOI] [PubMed] [Google Scholar]
  45. Ribi E. Beneficial modification of the endotoxin molecule. J Biol Response Mod. 1984;3(1):1–9. [PubMed] [Google Scholar]
  46. Ribi E., Cantrell J. L., Takayama K., Qureshi N., Peterson J., Ribi H. O. Lipid A and immunotherapy. Rev Infect Dis. 1984 Jul-Aug;6(4):567–572. doi: 10.1093/clinids/6.4.567. [DOI] [PubMed] [Google Scholar]
  47. Rickman L. S., Gordon D. M., Wistar R., Jr, Krzych U., Gross M., Hollingdale M. R., Egan J. E., Chulay J. D., Hoffman S. L. Use of adjuvant containing mycobacterial cell-wall skeleton, monophosphoryl lipid A, and squalane in malaria circumsporozoite protein vaccine. Lancet. 1991 Apr 27;337(8748):998–1001. doi: 10.1016/0140-6736(91)92659-p. [DOI] [PubMed] [Google Scholar]
  48. Schneerson R., Fattom A., Szu S. C., Bryla D., Ulrich J. T., Rudbach J. A., Schiffman G., Robbins J. B. Evaluation of monophosphoryl lipid A (MPL) as an adjuvant. Enhancement of the serum antibody response in mice to polysaccharide-protein conjugates by concurrent injection with MPL. J Immunol. 1991 Oct 1;147(7):2136–2140. [PubMed] [Google Scholar]
  49. Severinson E., Bergstedt-Lindqvist S., van der Loo W., Fernandez C. Characterization of the IgG response induced by polyclonal B cell activators. Immunol Rev. 1982;67:73–85. doi: 10.1111/j.1600-065x.1982.tb01056.x. [DOI] [PubMed] [Google Scholar]
  50. Sussman G., Wadee A. A. Supernatants derived from CD8+ lymphocytes activated by mycobacterial fractions inhibit cytokine production. The role of interleukin-6. Biotherapy. 1992;4(2):87–95. doi: 10.1007/BF02171753. [DOI] [PubMed] [Google Scholar]
  51. Takayama K., Ribi E., Cantrell J. L. Isolation of a nontoxic lipid A fraction containing tumor regression activity. Cancer Res. 1981 Jul;41(7):2654–2657. [PubMed] [Google Scholar]
  52. Tomai M. A., Johnson A. G. T cell and interferon-gamma involvement in the adjuvant action of a detoxified endotoxin. J Biol Response Mod. 1989 Dec;8(6):625–643. [PubMed] [Google Scholar]
  53. Tomai M. A., Solem L. E., Johnson A. G., Ribi E. The adjuvant properties of a nontoxic monophosphoryl lipid A in hyporesponsive and aging mice. J Biol Response Mod. 1987 Apr;6(2):99–107. [PubMed] [Google Scholar]
  54. Tsicopoulos A., Hamid Q., Varney V., Ying S., Moqbel R., Durham S. R., Kay A. B. Preferential messenger RNA expression of Th1-type cells (IFN-gamma+, IL-2+) in classical delayed-type (tuberculin) hypersensitivity reactions in human skin. J Immunol. 1992 Apr 1;148(7):2058–2061. [PubMed] [Google Scholar]
  55. Vogel S. N., Hilfiker M. L., Caulfield M. J. Endotoxin-induced T lymphocyte proliferation. J Immunol. 1983 Apr;130(4):1774–1779. [PubMed] [Google Scholar]
  56. Wherry J. C., Schreiber R. D., Unanue E. R. Regulation of gamma interferon production by natural killer cells in scid mice: roles of tumor necrosis factor and bacterial stimuli. Infect Immun. 1991 May;59(5):1709–1715. doi: 10.1128/iai.59.5.1709-1715.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES